CAG方案用于治疗相关性急性髓系白血病诱导化疗的临床观察  

Clinical observation of CAG regimen used in the induction chemotherapy of therapy-related acute myeloid leukemia

作　　者：罗贤生[1] 王智明[1] 黄海妹[1] 陈晓霞[1] 

机构地区：[1]海南省海口市人民医院血液科,海南海口570208

出　　处：《安徽医药》2014年第2期345-347,共3页Anhui Medical and Pharmaceutical Journal

摘　　要：目的观察CAG方案(阿克拉霉素+阿糖胞苷+粒细胞集落刺激因子)用于治疗相关性急性髓系白血病诱导化疗的疗效及不良反应。方法对13例治疗相关性急性髓系白血病患者采用CAG方案化疗2疗程的缓解率及不良反应进行统计分析。结果 13例治疗相关性急性髓系白血病采用CAG方案诱导化疗1疗程后完全缓解率53.8%(7/13),部分缓解率7.7%(1/13);化疗2疗程后完全缓解率69.2%(9/13)。主要不良反应为恶心、呕吐、骨髓抑制和感染。结论 CAG方案用于治疗相关性急性髓系白血病诱导化疗的有效率高,多数患者不良反应不严重,可作为一种安全有效的推荐方案。Objective To explore the curative effect and adverse reaction of CAG regimen（ Aclarubicin ＋ cytarabine ＋ granulocyte colony stimulating factor） used in the induction chemotherapy of therapy-related acute myeloid leukemia. Methods We counted and analysed the remission rate and adverse reaction of 13 patients with therapy-related acute myeloid leukemia treated by CAG regimen chemotherapy 2 courses. Results The complete remission rate of the 13 patients was 53. 8%（ 7 /13） after 1 course of chemotherapy and the partial remission rate was 7. 7%（ 1 /13）; the complete remission rate was 69. 2%（ 9 /13） after 2 courses of chemotherapy. Main adverse reaction were nausea,vomit,bone marrow suppression and infection. Conclusions CAG regimen used in the induction chemotherapy of therapy-related acute myeloid leukemia has high efficacy and most of the patients have no serious adverse reaction,which can be used as a safe and effective recommended therapy.

关 键 词：CAG方案 治疗相关性急性髓系白血病 诱导化疗 

分 类 号：R733.71[医药卫生—肿瘤]